Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17483824 | 1.00 | TP53 (0.50) | TP53ALDH1A1L3MBTL1LMNAGAA | |
| SCHEMBL2992794 | 0.74 | TP53 (0.57) | TP53ALDH1A1L3MBTL1LMNAGAA | |
| SCHEMBL2992791 | 0.74 | TP53 (0.57) | TP53ALDH1A1L3MBTL1LMNAGAA | |
| SCHEMBL2995405 | 0.71 | TP53 (0.53) | TP53ALDH1A1L3MBTL1GAACA1 | |
| SCHEMBL2995404 | 0.71 | TP53 (0.53) | TP53ALDH1A1L3MBTL1GAACA1 | |
| SCHEMBL2993893 | 0.71 | TP53 (0.60) | TP53ALDH1A1L3MBTL1LMNAGAA | |
| SCHEMBL2986200 | 0.70 | ALDH1A1 (0.83) | TP53ALDH1A1L3MBTL1GAACA1 | |
| SCHEMBL2992964 | 0.70 | ALDH1A1 (1.00) | TP53ALDH1A1L3MBTL1LMNAGAA | |
| SCHEMBL1415953 | 0.69 | TP53 (1.00) | TP53ALDH1A1L3MBTL1LMNAGAA | |
| SCHEMBL13381492 | 0.67 | ALDH1A1 (0.76) | TP53ALDH1A1L3MBTL1GAACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9504729-B2 | Antiangiogenic small molecules and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160030508-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-02-04 | — | — | US | disclosed |
| US-9186365-B2 | Antiangiogenic small molecules and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-11-17 | — | — | US | disclosed |
| US-20120129775-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030508-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | VEGFA, FLT4, KDR | TP53 356/4885ALDH1A1 1615/4885L3MBTL1 2769/4885 |
| US-20120129775-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | VEGFA, FLT4, KDR | TP53 356/4885ALDH1A1 1615/4885L3MBTL1 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.